Home
Conditions
Recurrent Follicular Lymphoma

Clinical trial condition

Recurrent Follicular Lymphoma

Explore clinical trials studying Recurrent Follicular Lymphoma. Study availability and eligibility vary by location and protocol.

31 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Follicular Lymphoma trial results

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Recruiting

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

NCT06948786

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +12 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

NCT06191887

Conditions: B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
Locations: Mayo Clinic in Florida Jacksonville, Florida, United States

View Trial Details

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

NCT04205409

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +46 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Completed

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

NCT01644799

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States

University of Chicago Chicago, Illinois, United States

Washington University School of Medicine St Louis, Missouri, United States

Weill Medical College of Cornell University New York, United States

View Trial Details

Completed

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

NCT03035331

Conditions: Aggressive Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +31 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

NCT01995669

Conditions: Chronic Disease, Disease Attributes, Grade 3a Follicular Lymphoma, +28 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

NCT04578600

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +39 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

NCT02927964

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +17 more
Locations: Stanford University, School of Medicine Palo Alto, California, United States

View Trial Details

Recurrent Follicular Lymphoma

Recurrent Follicular Lymphoma trial results

Related conditions